Skip to main content

Global Epilepsy Market Analysis on Revenue, Gross Margin Driving Essential Factors and Trends

Global Epilepsy Market Research Overview by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), by Diagnosis & Treatment (Diagnosis & Treatment), by End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), and Regional Analysis, Industry Size, Growth, Technology and Trend – Forecast till 2023
Epilepsy Market Size is Expected to touch a Global worth of USD 9,509.2 million by 2023, exhibiting a CAGR of 8.20% over the forecast period (2018-2023).
Epilepsy has been known as the fourth most prevalent neurological ailment. It is s chronic condition that triggers recurrent and unprovoked seizures. It can affect anyone irrespective of their ages.
World Health Organization records that in 2017, almost 50 million individuals throughout the world suffer from epilepsy, making it one of the most prevalent neurological disorders worldwide. Almost 80% of the people affected by epilepsy have been estimated to live in low- and middle-income economies.
Major Industry Competitive Analysis
Top Epilepsy Industry Key players in the Global Regional Landscapes given as Follows –
  • Eisai Co. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • GW Pharmaceuticals PLC
  • Abbott Laboratories
  • UCB SA
  • LivaNova PLC
  • Medtronic PLC
  • Johnson & Johnson Services Inc.
  • GlaxoSmithKline PLC
  • NeuroPace Inc.
  • and Others.
Epilepsy Market Segmentation
The global epilepsy market is segmented by condition, diagnosis & treatment, and end-user.
By condition, the epilepsy market is divided into epilepsy drug resistant/intractable epilepsy and others.
By diagnosis and treatment, the epilepsy market is segmented into diagnosis– imaging devices, blood tests, and others
and treatment- anti-epileptic drugs, neurostimulation devices, brain surgery, ketogenic diet, and others.
By end-user, the epilepsy market include hospitals, clinics, ambulatory surgical centers, diagnostic centers, and others.
Geographically the Epilepsy Market Has been Segmented into Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA). Among all the Americas leads the worldwide market for anti-epilepsy drugs on account of the growing incidents of epilepsy, availability of the advanced technologies, along with the enhanced healthcare infrastructure within the region. Europe holds the second share in the market owing to increasing healthcare outlays, surging healthcare R&D spending by the governing bodies, and rapid patient population.
Browse Complete Premium Report Details at: https://www.marketresearchfuture.com/reports/epilepsy-market-7730
The Asia Pacific region has been the fastest expanding market due to the presence of developing countries like China and India. These regions have large patient population and the countries are putting additional efforts in growing their healthcare outlays. And Middle East and Africa holds the least market share particularly because of the presence of strict government regulations and the poor economic conditions prevailing within the African market.
LIST OF TABLES
TABLE 1 MARKET SYNOPSIS
TABLE 2 PRIMARY INTERVIEWS
TABLE 3 GLOBAL EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 4 GLOBAL EPILEPSY MARKET, FOR EPILEPSY DRUG-RESISTANT/ INTRACTABLE EPILEPSY, BY REGION 2015–2023 (USD MILLION)
TABLE 5 GLOBAL EPILEPSY MARKET, FOR OTHERS, BY REGION 2015–2023 (USD MILLION)
TABLE 6 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 7 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2015-2023 (USD MILLION)
TABLE 8 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2015-2023 (USD MILLION)
TABLE 9 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 10 GLOBAL EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 11 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 12 GLOBAL EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
Continued…
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Labels:

Comments

Post a Comment

Popular posts from this blog

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La R...
3 comments
Read more

Peptic Ulcer Drugs Market Rapid Development By Manufactures Business Growth Future

  Peptic Ulcer Drugs Market Scenario: Peptic ulcer drugs are used to treat erosion of the gastrointestinal lining due to a variety of factors. Peptic ulcer is the result of an imbalance between aggressive and defensive fluids in the stomach. Peptic ulcer includes gastric, esophageal and duodenal ulcer. The global peptic ulcer drugs market was valued at approximately $29 billion in 2015, and is expected to reach $36.27 billion by 2022. Thus, the market is expected to show an average growth at a CAGR of 3.8 % from 2016 to 2022. The major driving factors for petic ulcers drug market are stress, drug induced ulcers, growing rate of infection by H.Pyrroli, changes in food, rise in cancer, tobacco and alcohol use. Constraining factors of this market are patent expiry, comparatively good treatment regimen of proton pump inhibitors, resistance of H.Pyrolli, extreme market fragmentation into many companies and great penetration of generics. Avail a Free Sample@  https://www.market...
Post a Comment
Read more

Middle East And Africa Pediatric Healthcare Market Development Research with Forthcoming Opportunities and Challenges

  Middle East And Africa Pediatric Healthcare Market Share, Application And Growth Analysis, By Type Of Diseases (Short Term Diseases, Chronic Diseases And Others), By Therapeutics (Cardiology, Allergy And Immunology, Gastroenterology, Infectious Disease And Others), By Treatment (Medication, Surgery, And Others) - Forecast To 2023 Paediatric Healthcare-Overview Paediatrics is a branch of medicine which deals with diagnosis and treatment of diseases related to paediatric group. It can be classified into the four categories namely neonates (from birth till the first 28 days of life), infants (29 days to 2 years), children (2 years to 12 years) and adolescents (12 years to 18 years). Paediatrician is a medical professional who specializes in providing treating the paediatric group. Paediatric medical devices are devices used for the treatment and care of infants and children below 18 years having some healthcare issues. Avail a Free Sample@  https://www.marketresearchfuture.com/...
Post a Comment
Read more